Immune globulin intravenous Side Effects
Some side effects of immune globulin intravenous may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to immune globulin intravenous: powder for solution, solution
Along with its needed effects, immune globulin intravenous may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking immune globulin intravenous:More common
- difficulty with breathing
- fast, pounding, or irregular heartbeat or pulse
- noisy breathing
- tightness in the chest
- troubled breathing
- unusual tiredness or weakness
- Bluish coloring of the lips or nailbeds
- burning sensation in the head
- faintness or lightheadedness
- Difficulty with swallowing
- hives or welts
- itching, especially of the feet or hands
- reddening of the skin, especially around the ears
- swelling of the eyes, face, or inside of the nose
- Back, leg, or stomach pains
- bleeding gums
- blistering, peeling, or loosening of the skin
- bloody, black, or tarry stools
- blurred vision
- change in consciousness
- chest pain or discomfort
- cold, clammy, or pale skin
- coughing that sometimes produces a pink frothy sputum
- dark urine
- decrease in urine amount
- dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
- fever with or without chills
- headache that is severe and occurs suddenly
- increased sweating
- light-colored stools
- loss of appetite
- loss of bladder control
- loss of consciousness
- low blood pressure or pulse
- muscle spasm or jerking of all extremities
- nausea or vomiting
- painful or difficult urination
- pains in the chest, groin, or legs, especially calves of the legs
- red skin lesions, often with a purple center
- red, irritated eyes
- shakiness in the legs, arms, hands, or feet
- skin blisters
- slurred speech that occurs suddenly
- slow breathing
- sores, ulcers, or white spots in the mouth or on the lips
- sudden loss of consciousness
- sudden loss of coordination
- sudden vision changes
- sudden, severe weakness or numbness in the arm or leg
- swelling in the legs and ankles
- tightness in the chest
- trembling or shaking of the hands or feet
- unusual bleeding or bruising
- yellow eyes or skin
Some side effects of immune globulin intravenous may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
- joint pain
- muscle pain
- redness, swelling, itching, or pain at the injection site
- skin rash
- Hip pain
- leg cramps
- Feeling of warmth
- redness of the face, neck, arms, and occasionally, upper chest
- stomach pain
- swollen glands
For Healthcare Professionals
Applies to immune globulin intravenous: intravenous powder for injection, intravenous solution
In general, immune globulin intravenous human (IGIV) has been well tolerated. Mild infusion related symptoms of headache, myalgia, backache, fever, pruritus, hypotension/hypertension, tachycardia, chest tightness, chills, flushing, and nausea have been reported. Slowing or temporarily discontinuing the infusion has usually resulted in resolution of symptoms.
Renal side effects have included acute renal failure, acute tubular necrosis, proximal tubular nephropathy, and osmotic nephrosis, primarily in patients with baseline renal impairment. Some patients have required dialysis. Elevations in creatinine and BUN have been noted within 1 to 2 days following infusion. The incidence of adverse reactions may be greater in products containing sucrose as a stabilizer. Maltose containing products may cause mild diuresis. At least one case of reversible oliguria requiring only supportive care and renal failure requiring transplantation in a patient with baseline renal dysfunction has also been reported.
Twenty cases of IGIV related renal impairment have been reported.
Renal impairment, including renal failure, usually occurred in the first 5 days of therapy and more frequently in patients receiving high IGIV dosages for immune thrombocytopenia purpura.
Spontaneous reports to one manufacturer suggest that diabetic patients over the age of 70 years and patients with lupus nephritis receiving dosages greater than 400 mg/kg/day may be at increased risk of renal impairment. The mechanism has not been fully established, but may be related to renal tubular sucrose-induced osmotic injury or an immune mechanism.
Hypersensitivity side effects have included responses in the form of an inflammatory reaction (fever, chills, nausea, vomiting, hypotension) in 10% of patients with agammaglobulinemia or severe hypogammaglobulinemia who have not received IGIV within 8 weeks or who have never received IGIV. True anaphylaxis, rarely resulting in death, has been reported.
Anaphylaxis has occurred more frequently in patients with previous severe hypersensitivity reactions to IGIV, but has been reported in patients without a history of IGIV allergy. Patients previously sensitized to antibodies, such as IgA, may be at increased risk for immediate hypersensitivity reactions. Epinephrine, oxygen, IV antihistamines, and IV corticosteroids should be immediately available as such reactions can occur seconds to hours after the initiation of the infusion.
Limited data suggest that a history of migraine headaches may be associated with an increased risk of aseptic meningitis syndrome.
Nervous system side effects have been reported rarely. Mild, post infusion headache has been reported in 2% of patients with Immune Thrombocytopenic Purpura (ITP) who received dosages equal to or greater than 0.4 g/kg/day. An Aseptic Meningitis Syndrome (AMS), primarily associated with dosages greater than 2 g/kg, has occasionally been reported. Discontinuation of IGIV has resulted in AMS resolution without sequelae. Rarely, seizures have been reported.
Metabolic side effects have been reported rarely. Hyponatremia has been reported in products containing 10% maltose.
Hematologic side effects have been reported rarely. These have included reports of mild hemolysis due to transfer of blood group antibodies, and thrombotic complications. At least 6 cases of disseminated intravascular coagulation (DIC) associated with acute hemoglinemia or hemoglobinuria following immune globulin intravenous administration have been reported.
A recent report of two women who received high dose IVIg and subsequently developed thromboembolic complications suggests that high-dose IVIg increases blood viscosity that may last for several weeks, which may increase susceptibility to thromboembolism in predisposed patients.
Out of the 6 patients who developed DIC, 1 child recovered without sequelae and 5 adults all died. The attending or consulting physicians assessed that acute hemolysis or DIC caused or contributed to each death.
Cardiovascular side effects have included rare reports of cardiovascular and cerebrovascular thrombosis.
IGIV products with a more acidic pH have been reported to cause greater vein irritation.
Local side effects have included injection site reactions. These have included erythema, pain, infection, venous thrombosis, thrombophlebitis, and eczema.
Immunologic side effects have been reported rarely. All U.S. immune globulin products undergo viral inactivation and/or removal. However, no method has been totally effective in removing all risk and the potential exists for the presence of unknown infectious agents.
More immune globulin intravenous resources
- Bivigam Advanced Consumer (Micromedex) - Includes Dosage Information
- Carimune Prescribing Information (FDA)
- Flebogamma MedFacts Consumer Leaflet (Wolters Kluwer)
- Flebogamma Prescribing Information (FDA)
- Gammaplex Prescribing Information (FDA)
- Gammar-P I.V.
- Gammar-P I.V. Consumer Overview
- Gamunex MedFacts Consumer Leaflet (Wolters Kluwer)
- Gamunex Consumer Overview
- Octagam Prescribing Information (FDA)
- Octagam Consumer Overview
- Privigen Prescribing Information (FDA)
- Privigen Consumer Overview
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.